Atlantic Veterinary College initiates clinical trial for treatment of cardiac tumours in dogs

| Atlantic Veterinary College
Drs. Etienne Côté, Abigail Martin, and Lynne O’Sullivan, co-lead investigators on clinical trials to treat cardiac tumours in dogs
Drs. Etienne Côté, Abigail Martin, and Lynne O’Sullivan, co-lead investigators on clinical trials to treat cardiac tumours in dogs

The Atlantic Veterinary College (AVC) at the University of Prince Edward Island (UPEI) is launching a groundbreaking clinical trial aimed at treating cardiac tumors in dogs using a medication commonly prescribed for children.

Cardiac tumours predominantly affect large breed dogs and are often diagnosed only after they are admitted into an emergency hospital where the condition presents as fluid around the heart. Under the leadership of Drs. Abigail Martin, Etienne Côté, and Lynne O’Sullivan, the AVC is investigating the use of propranolol, a medication used in the treatment of similar conditions in children.

"Propranolol has shown great success in treating hemangiomas in infants,” said Martin, co-lead investigator. “We want to see if it can have a similar effect on dogs, as treatment options for this condition are limited and often result in end-of-life-conversations.”

The trial represents a significant advancement in veterinary cardiology, exploring therapies where few options previously existed.

“Right now, we can help the patient in the short term by relieving the fluid around the heart, so it helps the dog feel better,” said Côté, co-lead of the clinical trial and professor of cardiology at AVC. “However, the underlying issue is the tumour, and surgery is often not viable. We want to know if this medication will help shrink the tumor and enhance the quality of life for these animals.”

This innovative research is supported by the Arthur L. Irving Foundation, the ACVIM Cardiology Pacemaker Fund Research Grant, and AVC’s Companion Animal Fund, highlighting the College’s commitment to advancing veterinary medicine and improving animal health. The trial will continue for up to two years.

Dogs eligible for the trial must be referred to AVC by their veterinarian and meet specific criteria. Once enrolled, patients will receive trial medication orally at home for one month, with ongoing monitoring by AVC’s veterinary specialists.

AVC encourages dog owners who believe their pets may benefit from this study to consult their veterinarian for referral and eligibility information.

Media Contact

Anna MacDonald
Communications Officer
Marketing and Communications
902-566-0949

Relevant Links